Article

Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

National Institutes of Health, Bethesda, MD, USA.
The Journal of urology (Impact Factor: 3.75). 02/2009; 181(4):1642-57. DOI: 10.1016/j.juro.2009.01.071
Source: PubMed

ABSTRACT To develop an evidence-based guideline on the use of 5-alpha-reductase inhibitors (5-ARIs) for prostate cancer chemoprevention.
The American Society of Clinical Oncology (ASCO) Health Services Committee (HSC), ASCO Cancer Prevention Committee, and the American Urological Association Practice Guidelines Committee jointly convened a Panel of experts, who used the results from a systematic review of the literature to develop evidence-based recommendations on the use of 5-ARIs for prostate cancer chemoprevention.
The systematic review completed for this guideline identified 15 randomized clinical trials that met the inclusion criteria, nine of which reported prostate cancer period prevalence.
Asymptomatic men with a prostate-specific antigen (PSA) </=3.0 ng/mL who are regularly screened with PSA or are anticipating undergoing annual PSA screening for early detection of prostate cancer may benefit from a discussion of both the benefits of 5-ARIs for 7 years for the prevention of prostate cancer and the potential risks (including the possibility of high-grade prostate cancer). Men who are taking 5-ARIs for benign conditions such as lower urinary tract [obstructive] symptoms (LUTS) may benefit from a similar discussion, understanding that the improvement of LUTS relief should be weighed with the potential risks of high-grade prostate cancer from 5-ARIs (although the majority of the Panel members judged the latter risk to be unlikely). A reduction of approximately 50% in PSA by 12 months is expected in men taking a 5-ARI; however, because these changes in PSA may vary across men, and within individual men over time, the Panel cannot recommend a specific cut point to trigger a biopsy for men taking a 5-ARI. No specific cut point or change in PSA has been prospectively validated in men taking a 5-ARI.

0 Bookmarks
 · 
84 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Einleitung Ziel dieser Studie war es zu evaluieren, wie in Deutschland praktizierende Fachärzte für Urologie der DGU Prostatastanzbiopsien (Bx) durchführen und wie pathohistologische Befundberichte von Ihnen genutzt werden, um Behandlungsentscheidungen zu treffen. Material und Methoden Ein 5-seitiger anonymer Fragebogen wurde entwickelt, um verschiedene Inhalte zu Bx bzw. pathohistologischen Befundberichten abzufragen. Zudem wurden 4 hypothetische klinische Situationen konstruiert, die komplexe Behandlungsentscheidungen erfordern Ergebnisse Der Fragebogen wurde von 95 von 282 Urologen (33%) beantwortet. Die Teilnehmer verfügten über eine durchschnittliche urologische Berufstätigkeit von 13 (0,5–38) Jahren, 22 (23%) Urologen führten selbst radikale Prostatovesikulektomien durch, 73 (77%) Urologen waren in dieser Hinsicht rein konservativ tätig. Zweiunddreißig (34%) Urologen nahmen bei der Erstbiopsie 6–8 Scores, 55 (58%) Urologen 10–12 Scores, 6 (6%), > 12 Scores. Urologen mit einer Berufserfahrung < 15 Jahren 73 (77%) entnahmen deutlich mehr Bx. Der primäre und sekundäre Gleason-Score waren für nur 36 (38%) der antwortenden Ärzte zur Erstellung eines Behandlungsplans wichtig. Bei Nachweis von einzelnen Prostatakarzinomzellnester im Befundbericht war für nur 44 (48%) zusätzlich der Gleason-Score in der initialen Histologie von Bedeutung. Weitere Parameter, die von Urologen in pathologischen Befundberichten zur Therapieplanung als wichtig erachtet wurden, waren perineurale Invasion (60%), periprostatische Infiltration (57%), Kapselperforation (57%) und prozentuale Infiltration der Stanzzylinder (13%). Interessanterweise benutzten 84 (88%) der Teilnehmer bei Bx mit multiplen positiven Stanzzylinder aus verschiedenen Lokalisationen den höchsten Gleason-Score zur Therapieentscheidung. Atypische kleine azinäre Proliferation (ASAP) in Bx wurde nur von 43 (44%) Urologen als Indikation zur Rebiopsie angesehen, für die High-grade-PIN war dies bei 49 (53%) der Fall. Schlussfolgerung Die Untersuchung an unserem Kollektiv von 95 Urologen zeigt zum einen eine große Variabilität bei der Durchführung von Prostatastanzbiopsien, zum anderen, dass pathohistologische Befundberichte für Behandlungsentscheidungen sehr unterschiedlich bewertet werden. Unsere Studie unterstreicht die Notwendigkeit, die Kommunikation mit dem Pathologen zu optimieren und Parameter, die für die individuelle Therapieplanung von Bedeutung sind, besser zu definieren und deren Implementierung in die klinische Praxis zu verbessern.
    Der Urologe 02/2012; 52(2). · 0.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: This study was conducted to examine the effect of discontinuing tamsulosin in patients with benign prostatic hyperplasia who had been receiving combination therapy with tamsulosin and dutasteride.Methods: The study sample consisted of 108 men with benign prostatic hyperplasia and lower urinary tract symptoms who visited our urology clinics between April 2008 and December 2010. All were assessed using the International Prostate Symptom Score (IPSS). The patients had IPSS of 8–19 and prostate volumes ≥25 mL by transrectal ultrasonography. They were put on tamsulosin and dutasteride, and the efficacy of this regimen was assessed every 12 weeks. After 48 weeks, patients were divided at random into a group continuing to take the same drug combination (group 1) and a group taking only dutasteride 0.5 mg (group 2).Results: Sixty-nine of the original 108 patients completed the study, 36 (52%) in group 1 and 33 (48%) in group 2. The mean age of all patients was 67.96 ± 7.88 years and mean prostatic volume was 40.45 ± 12.81 mL. Mean prostate-specific antigen was 3.31 (0.4–9.9) ng/mL at the outset. The IPSS scores of the two groups at first visit, 48 and 72 weeks were, respectively, 14.69 versus 15.85 (P = 0.322), 12.08 versus 12.85 (P = 0.582) and 10.89 versus 11.06 (P = 0.897.) There was a statistically significant difference between the baseline and 72-week IPSS scores in both groups (group 1: P < 0.001, group 2: P < 0.001).Conclusion: In patients with moderate IPSS, discontinuing tamsulosin after 48 weeks of combined tamsulosin and dutasteride therapy has no significant effect on outcome.
    Lower urinary tract symptoms 01/2012; 4(1). · 0.54 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To summarize the history of the use of 5-alpha-reductase inhibitors in the treatment of urologic diseases and discuss the current practices and indications for therapy.
    Current Opinion in Endocrinology Diabetes and Obesity 09/2014; · 3.77 Impact Factor